A Study Comparing Eribulin Mesylate and Ixabepilone in Causing or Exacerbating Neuropathy in Participants With Advanced Breast Cancer
A Phase II, Multicenter, Randomized, Open-Label Study Comparing Eribulin Mesylate and Ixabepilone in Causing or Exacerbating Neuropathy in Patients With Advanced Breast Cancer
Sponsor: Eisai Inc.
Listed as NCT00879086, this PHASE2 trial focuses on Breast Cancer and remains completed. Sponsored by Eisai Inc., it has been updated 9 times since 2009, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
9 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE2
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Jul 2023 — Jul 2024 [monthly]
Completed PHASE2
-
Jan 2022 — Jul 2023 [monthly]
Completed PHASE2
▶ Show 4 earlier versions
-
Jan 2021 — Jan 2022 [monthly]
Completed PHASE2
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE2
-
Feb 2017 — Jun 2018 [monthly]
Completed PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Completed PHASE2
First recorded
Mar 2009
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Eisai Inc.
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Austin, United States , Berkeley Heights, United States , Boca Raton, United States , Brownstown, United States , Charleston, United States , Chicago, United States , Columbia, United States , Corpus Christi, United States , Council Bluffs, United States , Dallas, United States and 32 more locations